The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 01, 2019

Filed:

Dec. 03, 2018
Applicants:

Shanghai Hansoh Biomedical Co., Ltd., Shanghai, CN;

Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Lianyungang, Jiangsu, CN;

Inventors:

Mingsong Wei, Shanghai, CN;

Guangjun Sun, Shanghai, CN;

Songliang Tan, Shanghai, CN;

Peng Gao, Shanghai, CN;

Shaobao Wang, Shanghai, CN;

Wenhua Xiu, Shanghai, CN;

Fujun Zhang, Shanghai, CN;

Rudi Bao, Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/04 (2006.01); C07D 491/107 (2006.01); C07D 403/12 (2006.01); C07D 405/14 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 31/675 (2006.01); C07F 9/53 (2006.01); C07D 403/04 (2006.01); C07D 405/12 (2006.01); C07D 239/48 (2006.01); C07D 471/10 (2006.01); C07D 413/14 (2006.01); C07D 471/06 (2006.01); C07D 491/10 (2006.01);
U.S. Cl.
CPC ...
C07D 491/107 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/675 (2013.01); C07D 239/48 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 471/06 (2013.01); C07D 471/10 (2013.01); C07D 491/10 (2013.01); C07F 9/53 (2013.01);
Abstract

Epidermal growth factor receptor (EGFR) inhibitors are provided. In particular, 4-substituted-2-(N-(5-substituted ally amide)phenyl)amino)pyrimidine derivatives of formula (I), a preparation method and use thereof as an EGFR inhibitor are provided. The 4-substituted-2-(N-(5-substituted ally amide)phenyl)amino)pyrimidine derivatives of formula (I) have inhibitory activity against the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, and can be used to treat diseases mediated alone or in part by EGFR mutant activity. The derivatives of formula (I) can be used to treat and/or prevent cancers, particularly non-small cell lung cancer.


Find Patent Forward Citations

Loading…